Abstract: The disclosure relates generally to biology and medicine, and more particularly it relates to compounds acting as half-life (t½)-extending moieties for use with therapeutics, especially for improving t½ of biological-based therapeutics (i.e., biotherapeutics or biologics). The disclosure further relates to fusions and conjugates that include one or more of the compounds acting as t½-extending moieties, as well as pharmaceutical compositions including the same and their use in treating various conditions, diseases or disorders.
| # | Name | Date |
|---|---|---|
| 1 | 202317047517-STATEMENT OF UNDERTAKING (FORM 3) [14-07-2023(online)].pdf | 2023-07-14 |
| 2 | 202317047517-Sequence Listing in txt [14-07-2023(online)].txt | 2023-07-14 |
| 3 | 202317047517-Sequence Listing in PDF [14-07-2023(online)].pdf | 2023-07-14 |
| 4 | 202317047517-POWER OF AUTHORITY [14-07-2023(online)].pdf | 2023-07-14 |
| 5 | 202317047517-NOTIFICATION OF INT. APPLN. NO. & FILING DATE (PCT-RO-105-PCT Pamphlet) [14-07-2023(online)].pdf | 2023-07-14 |
| 6 | 202317047517-FORM 1 [14-07-2023(online)].pdf | 2023-07-14 |
| 7 | 202317047517-DECLARATION OF INVENTORSHIP (FORM 5) [14-07-2023(online)].pdf | 2023-07-14 |
| 8 | 202317047517-COMPLETE SPECIFICATION [14-07-2023(online)].pdf | 2023-07-14 |
| 9 | 202317047517-CLAIMS UNDER RULE 1 (PROVISIO) OF RULE 20 [14-07-2023(online)].pdf | 2023-07-14 |
| 10 | 202317047517-FORM-26 [17-07-2023(online)].pdf | 2023-07-17 |
| 11 | 202317047517-Proof of Right [18-08-2023(online)].pdf | 2023-08-18 |
| 12 | 202317047517-Information under section 8(2) [07-12-2023(online)].pdf | 2023-12-07 |
| 13 | 202317047517-FORM 3 [07-12-2023(online)].pdf | 2023-12-07 |
| 14 | 202317047517-FORM 18 [21-01-2025(online)].pdf | 2025-01-21 |